Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma

Experimental and Molecular Pathology

Volumn 95, Issue 2, 2013, Pages 156-165

  Kuphal, Silke ^a   Wallner, Susanne ^a   Bosserhoff, Anja K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

LIF; Melanoma; Stem cell marker

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LEUKEMIA INHIBITORY FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOGENIC PROTEIN 1; STAT3 PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ARTICLE; CANCER STEM CELL; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; HYPOXEMIA; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTASIS; PRIMARY TUMOR; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; UPREGULATION;

2,2 DIPYRIDYL; ACTIVATOR PROTEIN 1; ANGIOPOIETIN-LIKE 4; ANGPTL4; AP-1; DESFERRIOXAMINE; DFX; DP; GAPDH; GASTRULATION BRAIN HOMEOBOX 2; GBX2; GLYCERALDEHYDES-3-PHOSPHATE DEHYDROGENASE; HIF-1; HYPOXIA INDUCIBLE FACTOR; KLF4; KRUPPEL-LIKE FACTOR 4; LEUKEMIA INHIBITORY FACTOR; LIF; MELANOMA; NF-ΚB; NUCLEAR FACTOR KAPPA B; OCT3/4; OCTAMER-BINDING TRANSCRIPTION FACTORS 3 AND 4; PHOSPHOTIDYLINOSITOL 3-KINASE; PI3K; SOX2; SRY SEX DETERMINING REGION Y-BOX 2; STEM CELL MARKER; T-BOX TRANSCRIPTION FACTOR; TBX3;

BLOTTING, WESTERN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUKEMIA INHIBITORY FACTOR; MELANOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84880635958     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.06.012     Document Type: Article

References (39)

1. Alexander H.R., Billingsley K.G., Block M.I., Fraker D.L. D-factor/leukaemia inhibitory factor: evidence for its role as a mediator in acute and chronic inflammatory disease. Cytokine 1994, 6(6):589-596.
2. Auernhammer C.J., Melmed S. Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocrine Reviews 2000, 21(3):313-345.
3. Bosserhoff A.K., Ellmann L., Kuphal S. Melanoblasts in culture as an in vitro system to determine molecular changes in melanoma. Experimental Dermatology 2011, 20(5):435-440.
4. Brown P.H., Chen T.K., Birrer M.J. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 1994, 9(3):791-799.
5. Casanova E.A., Shakhova O., Patel S.S., Asner I.N., Pelczar P., Weber F.A., et al. Pramel7 mediates LIF/STAT3-dependent self-renewal in embryonic stem cells. Stem Cells 2011, 29(3):474-485.
6. Cook A.L., Donatien P.D., Smith A.G., Murphy M., Jones M.K., Herlyn M., et al. Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. The Journal of Investigative Dermatology 2003, 121(5):1150-1159.
7. Gao A.C., Isaacs J.T. Expression of homeobox gene-GBX2 in human prostatic cancer cells. Prostate 1996, 29(6):395-398.
8. Gearing D.P., Gough N.M., King J.A., Hilton D.J., Nicola N.A., Simpson R.J., et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO Journal 1987, 6(13):3995-4002.
9. Gearing D.P., Druck T., Huebner K., Overhauser J., Gilbert D.J., Copeland N.G., et al. The leukemia inhibitory factor receptor (LIFR) gene is located within a cluster of cytokine receptor loci on mouse chromosome 15 and human chromosome 5p12-p13. Genomics 1993, 18(1):148-150.
10. Greber B., Lehrach H., Adjaye J. Control of early fate decisions in human ES cells by distinct states of TGFbeta pathway activity. Stem Cells and Development 2008, 17(6):1065-1077.
11. Heymann D., Harb J., Ringeard S., Blanchard F., Lassort D., Raher S., et al. Upmodulation of alpha v beta 1 integrin expression on human tumor cells by human interleukin for DA cells/leukemia inhibitory factor and oncostatin M: correlation with increased cell adhesion on fibronectin. Journal of Cellular Biochemistry 1995, 58(3):305-314.
12. Heymann D., Godard A., Raher S., Ringeard S., Lassort D., Blanchard F., et al. Human interleukin for DA cells/leukemia inhibitory factor and oncostatin M enhance membrane expression of intercellular adhesion molecule-1 on melanoma cells but not the shedding of its soluble form. Cytokine 1995, 7(2):111-117.
13. Hu J., Ono S., Katayama H., Imai T., Shimizu N., Nakagawa H. Leukemia inhibitory factor induces epidermal hyperplasia in patients with amyotrophic lateral sclerosis. The Journal of Investigative Dermatology 2000, 115(3):486-492.
14. Humphrey R.K., Beattie G.M., Lopez A.D., Bucay N., King C.C., Firpo M.T., et al. Maintenance of pluripotency in human embryonic stem cells is STAT3 independent. Stem Cells 2004, 22(4):522-530.
15. Kamohara H., Sakamoto K., Ishiko T., Mita S., Masuda Y., Abe T., et al. Human carcinoma cell lines produce biologically active leukemia inhibitory factor (LIF). Research Communications in Molecular Pathology and Pharmacology 1994, 85(2):131-140.
16. Kawashima T., Bao Y.C., Nomura Y., Moon Y., Tonozuka Y., Minoshima Y., et al. Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors. The Journal of Cell Biology 2006, 175(6):937-946.
17. Knight D. Leukaemia inhibitory factor (LIF): a cytokine of emerging importance in chronic airway inflammation. Pulmonary Pharmacology & Therapeutics 2001, 14(3):169-176.
18. Kuphal S., Winklmeier A., Warnecke C., Bosserhoff A.K. Constitutive HIF-1 activity in malignant melanoma. European Journal of Cancer 2010, 46(6):1159-1169.
19. Ling G.Q., Chen D.B., Wang B.Q., Zhang L.S. Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines. Oncology Letters 2012, 4(6):1264-1268.
20. Maruta S., Takiguchi S., Ueyama M., Kataoka Y., Oda Y., Tsuneyoshi M., et al. A role for leukemia inhibitory factor in melanoma-induced bone metastasis. Clinical & Experimental Metastasis 2009, 26(2):133-141.
21. McKenzie R.C., Szepietowski J. Cutaneous leukemia inhibitory factor and its potential role in the development of skin tumors. Dermatologic Surgery 2004, 30(2 Pt 2):279-290.
22. Meyskens F.L., Farmer P., Fruehauf J.P. Redox regulation in human melanocytes and melanoma. Pigment Cell Research 2001, 14(3):148-154.
23. Nakai-Futatsugi Y., Niwa H. Transcription factor network in embryonic stem cells: heterogeneity under the stringency. Biological and Pharmaceutical Bulletin 2013, 36(2):166-170.
24. Niu G., Bowman T., Huang M., Shivers S., Reintgen D., Daud A., et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002, 21(46):7001-7010.
25. Niwa H., Ogawa K., Shimosato D., Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 2009, 460(7251):118-122.
26. Oh H., Fujio Y., Kunisada K., Hirota H., Matsui H., Kishimoto T., et al. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. Journal of Biological Chemistry 1998, 273(16):9703-9710.
27. Paglia D., Oran A., Lu C., Kerbel R.S., Sauder D.N., McKenzie R.C. Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated. Journal of Interferon and Cytokine Research 1995, 15(5):455-460.
28. Paglia D., Kondo S., Ng K.M., Sauder D.N., McKenzie R.C. Leukaemia inhibitory factor is expressed by normal human keratinocytes in vitro and in vivo. British Journal of Dermatology 1996, 134(5):817-823.
29. Rathjen P.D., Toth S., Willis A., Heath J.K., Smith A.G. Differentiation inhibiting activity is produced in matrix-associated and diffusible forms that are generated by alternate promoter usage. Cell 1990, 62(6):1105-1114.
30. Rothhammer T., Poser I., Soncin F., Bataille F., Moser M., Bosserhoff A.K. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Research 2005, 65(2):448-456.
31. Salas E.M., Garcia-Barchino M.J., Labiano S., Shugay M., Perez-Encinas M., Quinteiro C., et al. LIF, a Novel STAT5-Regulated gene, is aberrantly expressed in myeloproliferative neoplasms. Genes Cancer 2011, 2(5):593-596.
32. Simpson R.J., Hilton D.J., Nice E.C., Rubira M.R., Metcalf D., Gearing D.P., et al. Structural characterization of a murine myeloid leukaemia inhibitory factor. European Journal of Biochemistry 1988, 175(3):541-547.
33. Szepietowski J.C., Walker C., McKenna D.B., Hunter J.A., McKenzie R.C. Leukaemia inhibitory factor and interleukin-8 expression in nonmelanoma skin cancers. Clinical and Experimental Dermatology 2001, 26(1):72-78.
34. Thoma B., Bird T.A., Friend D.J., Gearing D.P., Dower S.K. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. Journal of Biological Chemistry 1994, 269(8):6215-6222.
35. Turnley A.M., Bartlett P.F. Cytokines that signal through the leukemia inhibitory factor receptor-beta complex in the nervous system. Journal of Neurochemistry 2000, 74(3):889-899.
36. Wei C.L., Miura T., Robson P., Lim S.K., Xu X.Q., Lee M.Y., et al. Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells 2005, 23(2):166-185.
37. Wittgen H.G., van Kempen L.C. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Research 2007, 17(6):400-409.
38. Xu C., Inokuma M.S., Denham J., Golds K., Kundu P., Gold J.D., et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nature Biotechnology 2001, 19(10):971-974.
39. Ying Q.L., Nichols J., Chambers I., Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 2003, 115(3):281-292.